As a result, the amino‐terminal fragment of PTH (PTH1‐34, teriparatide or Forteo) became the first osteoanabolic treatment approved by the US FDA for treatment of patients with primary (Neer et al. 2001) or secondary osteoporosis due to glucocorticoid therapy who have a high risk of fracture (Saag et al. 2007). The gene discussed is PTH; the disease is osteoporosis.